[go: up one dir, main page]

MX2019001905A - Peptido objetivo de tumor maligno. - Google Patents

Peptido objetivo de tumor maligno.

Info

Publication number
MX2019001905A
MX2019001905A MX2019001905A MX2019001905A MX2019001905A MX 2019001905 A MX2019001905 A MX 2019001905A MX 2019001905 A MX2019001905 A MX 2019001905A MX 2019001905 A MX2019001905 A MX 2019001905A MX 2019001905 A MX2019001905 A MX 2019001905A
Authority
MX
Mexico
Prior art keywords
amino acid
acid sequence
malignant tumor
target peptide
symbol
Prior art date
Application number
MX2019001905A
Other languages
English (en)
Inventor
Fukuda Michiko
Nonaka Motohiro
Original Assignee
Aist
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aist filed Critical Aist
Publication of MX2019001905A publication Critical patent/MX2019001905A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0812—Tripeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/03—Peptides having up to 20 amino acids in an undefined or only partially defined sequence; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
    • A61K49/0056—Peptides, proteins, polyamino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/04—X-ray contrast preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/085—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier conjugated systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/14—Peptides, e.g. proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4721—Lipocortins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0821—Tripeptides with the first amino acid being heterocyclic, e.g. His, Pro, Trp
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G69/00—Macromolecular compounds obtained by reactions forming a carboxylic amide link in the main chain of the macromolecule
    • C08G69/02—Polyamides derived from amino-carboxylic acids or from polyamines and polycarboxylic acids
    • C08G69/08—Polyamides derived from amino-carboxylic acids or from polyamines and polycarboxylic acids derived from amino-carboxylic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Radiology & Medical Imaging (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Physics & Mathematics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Optics & Photonics (AREA)
  • Polymers & Plastics (AREA)
  • Toxicology (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente invencion proporciona un peptido que contiene la secuencia de aminoacidos de cualquiera de las formulas (I)-(III) a continuacion: (I) una secuencia de aminoacidos de(X1)[D]P[D](X2)[D] en donde X1 es W o F, X2 es S o T, y cada simbolo de aminoacido seguida inmediatamente por el simbolo [D] es una forma D del aminoacido, (II) una secuencia de aminoácidos de P[D]T[D](X)nF[D] en donde (X)n es cualquier aminoacido en el numero de n seleccionado independientemente entre si, n es un numero entero de 0-4, y el simbolo [D] es como se define arriba, (III) una secuencia de aminoacidos que es un Retro-inverso de la secuencia de aminoacidos de cualquiera de (I) y (II)antes mencionada; y un conjugado que contiene el peptido y una parte funcional.
MX2019001905A 2016-08-16 2017-08-16 Peptido objetivo de tumor maligno. MX2019001905A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2016159743 2016-08-16
PCT/JP2017/030003 WO2018034356A1 (ja) 2016-08-16 2017-08-16 悪性腫瘍標的ペプチド

Publications (1)

Publication Number Publication Date
MX2019001905A true MX2019001905A (es) 2019-05-15

Family

ID=61196808

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019001905A MX2019001905A (es) 2016-08-16 2017-08-16 Peptido objetivo de tumor maligno.

Country Status (17)

Country Link
US (2) US10695396B2 (es)
EP (1) EP3502122B1 (es)
JP (2) JP6666613B2 (es)
KR (1) KR102422174B1 (es)
CN (1) CN109563128B (es)
AU (1) AU2017311927B2 (es)
BR (1) BR112019002510A2 (es)
CA (1) CA3032775C (es)
ES (1) ES2901232T3 (es)
IL (1) IL264845B2 (es)
MX (1) MX2019001905A (es)
PH (1) PH12019500306B1 (es)
PL (1) PL3502122T3 (es)
PT (1) PT3502122T (es)
RU (1) RU2770197C2 (es)
WO (1) WO2018034356A1 (es)
ZA (1) ZA201901318B (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2019001905A (es) * 2016-08-16 2019-05-15 Aist Peptido objetivo de tumor maligno.
ES2928773T3 (es) 2017-01-17 2022-11-22 Heparegenix Gmbh Inhibidores de proteína cinasas para fomentar la regeneración hepática o reducir o prevenir la muerte de hepatocitos
CN112334158B (zh) * 2018-06-20 2023-10-13 国立大学法人弘前大学 用于硼中子俘获疗法的能够在短时间内选择性地或局部地靶向肿瘤组织的聚集性硼10药剂
JP7224628B2 (ja) * 2019-02-01 2023-02-20 国立研究開発法人産業技術総合研究所 抗ｍｃ１６抗体
CN113573783A (zh) * 2019-03-26 2021-10-29 株式会社岛津制作所 光免疫疗法及其使用的药剂
JP7429454B2 (ja) * 2019-03-26 2024-02-08 国立大学法人 新潟大学 ペプチド及びその使用
US20220227815A1 (en) * 2019-06-21 2022-07-21 University Of Kansas Compositions and methods useful in treating brain diseases
PH12022550039A1 (en) 2019-07-10 2023-06-26 Cybrexa 3 Inc Peptide conjugates of cytotoxins as therapeutics
MX2022000450A (es) 2019-07-10 2022-04-25 Cybrexa 3 Inc Conjugados peptídicos de agentes dirigidos a microtúbulos como terapéuticos.
CN113372415A (zh) * 2020-06-18 2021-09-10 长春理工大学 一种人膀胱癌特异性抗原结合肽
US20220072128A1 (en) * 2020-09-04 2022-03-10 The Board Of Trustees Of The Leland Stanford Junior University Ultrasound-induced convection for drug delivery and to drive glymphatic or lymphatic flows
KR102875469B1 (ko) 2022-11-25 2025-10-27 녹스팜 주식회사 암 표적 펩티드, 이를 포함하는 전구약물 나노입자 및 이를 포함하는 암 예방 또는 치료용 약학적 조성물
WO2025170315A1 (ko) * 2024-02-05 2025-08-14 주식회사 트리오어 이중 기능 도메인을 포함하는 융합단백질 및 이의 용도

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1577320E (pt) * 2004-03-19 2012-10-30 Pasteur Institut Péptidos derivados da proteína bplp humana, polinucleótidos que codificam para os referidos péptidos e anticorpos dirigidos contra os referidos péptidos
WO2010022444A1 (en) * 2008-08-25 2010-03-04 The Walter And Eliza Hall Institute Of Medical Research Methods and agents for modulating kinase signalling pathways through modulation of mixed-lineage kinase domain-like protein (mlkl)
US9610359B2 (en) * 2009-12-23 2017-04-04 Burnham Institute For Medical Research Methods and compositions related to annexin 1-binding compounds
JP5786204B2 (ja) * 2010-01-19 2015-09-30 イミューノメディクス、インコーポレイテッドＩｍｍｕｎｏｍｅｄｉｃｓ， Ｉｎｃ． インスリン様増殖因子ｉ型受容体（ｉｇｆ−１ｒ）を標的とする新規クラスの単一特異性ヒト化抗体および二重特異性ヒト化抗体
WO2015016768A1 (en) * 2013-07-29 2015-02-05 Temasek Life Sciences Laboratory Limited Jatropha curcas casbene synthase genes
JP6036878B2 (ja) 2015-02-27 2016-11-30 マツダ株式会社 四輪駆動車の制御装置
MX2019001905A (es) * 2016-08-16 2019-05-15 Aist Peptido objetivo de tumor maligno.
CN113573783A (zh) 2019-03-26 2021-10-29 株式会社岛津制作所 光免疫疗法及其使用的药剂

Also Published As

Publication number Publication date
AU2017311927B2 (en) 2021-06-03
CA3032775C (en) 2024-01-23
PH12019500306B1 (en) 2024-02-21
PT3502122T (pt) 2021-11-25
CN109563128B (zh) 2023-02-28
IL264845A (es) 2019-03-31
CA3032775A1 (en) 2018-02-22
JP2020079288A (ja) 2020-05-28
US20200323943A1 (en) 2020-10-15
ES2901232T3 (es) 2022-03-21
WO2018034356A1 (ja) 2018-02-22
US20190175684A1 (en) 2019-06-13
JP6666613B2 (ja) 2020-03-18
PH12019500306A1 (en) 2020-01-20
PL3502122T3 (pl) 2022-02-14
US10695396B2 (en) 2020-06-30
IL264845B1 (en) 2023-05-01
IL264845B2 (en) 2023-09-01
AU2017311927A1 (en) 2019-03-07
BR112019002510A2 (pt) 2019-06-25
JPWO2018034356A1 (ja) 2019-08-08
KR102422174B1 (ko) 2022-07-18
RU2770197C2 (ru) 2022-04-14
EP3502122A4 (en) 2020-04-01
RU2019107377A3 (es) 2020-12-17
EP3502122A1 (en) 2019-06-26
RU2019107377A (ru) 2020-09-18
CN109563128A (zh) 2019-04-02
KR20190039153A (ko) 2019-04-10
ZA201901318B (en) 2020-08-26
EP3502122B1 (en) 2021-10-20

Similar Documents

Publication Publication Date Title
PH12019500306A1 (en) Malignant tumor target peptide
PH12020500396A1 (en) Ectonucleotide pyrophosphatase-phosphodiesterase 1 (enpp-1) inhibitors and uses thereof
MX2019013387A (es) Dominio de union a antigeno.
WO2017025179A8 (en) A transglutamine tag for efficient site-specific bioconjugation
WO2015179635A3 (en) Ras inhibitory peptides and uses thereof
MX2018007680A (es) Acidos nucleicos que codifican secuencias repetitivas de aminoacidos ricas en residuos de prolina y alanina que tienen secuencias nucleotidicas con baja repetitividad.
JOP20200323A1 (ar) طرق لتصنيع تركيبات الأحماض الأمينية
MX2017009595A (es) Compuestos antisenescentes y usos de los mismos.
BR112018013246A2 (pt) rótulo de peptídeo e proteína rotulada incluindo o mesmo
CY1123840T1 (el) Οξινη συνθεση με βαση λεοναρδιτη και αμινοξεα
PH12017501520A1 (en) Fusarium toxin-cleaving polypeptide variants, additives containing same, use of same, and method for splitting fusarium toxins
MX2018004938A (es) Vacunas de antigeno ligado a pcrv de p. aeruginosa.
EP4374913A3 (en) Novel human serum albumin mutant
PH12017502213A1 (en) Compositions and methods for treating celiac sprue disease
BR112017018703A2 (pt) peptídeo derivado de gpc3, composição farmacêutica para tratamento ou prevenção de câncer usando o mesmo, indutor de imunidade, e método para produzir células de apresentação de antígeno
WO2015107363A3 (en) Mycobacterial antigen composition
MX2020007393A (es) Compuestos de fósforo(n)amidatacetal y fosf(on)atalcetal.
MX362058B (es) Péptido pntx(19) sintético, composición farmacéutica y uso.
MX2018014966A (es) Peptidos monolipidados resistentes a proteasas.
PH12017502323A1 (en) Novel xylanase
MX2018014490A (es) Peptido antimicrobiano modificado derivado de un dominio rico en arginina.
EP4282960A3 (en) Modified lipase and use thereof
WO2018065625A3 (en) Immunogenic compounds for cancer therapy
RU2018107330A (ru) Индуктор иммунитета
WO2021062389A3 (en) Peptide for treating cancer